Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound for modulating c-Kit activity according to Formula I,

or a pharmaceutically acceptable salt, thereof, wherein,

ring A is:

$(R^1)_{0-4}$	$(R^1)_{0-3}$	$(R^1)_{0-3}$
Z	$Z = \frac{1}{11}$ $N = \frac{1}{N}$ $(R^1)_{0-2}$	N - Z $N - Z$ $N -$
$(R^1)_{0-1}$	(R ¹) ₀₋₁	· N - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
(R ¹) ₀₋₄ Y	$(R^1)_{0-5}$ Z	$(R^1)_{0-5}$ Z Z
$(R^1)_{0-6}$ Y Y	(R ¹) ₀₋₆ Y Y	$(R^1)_{0-6} \xrightarrow{Y} \xrightarrow{Y}$

wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and $-N(R^7)$ -;

- each R1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -OR4, $-S(O)_{0-2}R^4$, $-SO_2N(R^4)R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-N(R^4)SO_2R^4$, $-N(R^4)C(O)R^4$, $-NCO_2R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;
- two adjacent of R¹, together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁰;

L¹ is a single bond;

ring B is a five- to ten-membered aryl or a five- to ten-membered heterocyclyl;

- each R² is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, $-S(O)_{0-2}R^4$, $-SO_2N(R^4)R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-N(R^4)SO_2R^4$, $-N(R^4)C(O)R^4$, $-NCO_2R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋ 6alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C1-6alkyl;
- two adjacent of R², together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁵;
- L^2 is selected from -N(H)N(H)C(=O)N(H)-, -CH₂N(H)C(=O)N(H)-, -CH₂OC(=O)N(H)-, and -XCH₂C(=O)N(H)-; wherein X is selected from -O-, -S(O)₀₋₂-, and -N(R⁷)-; and any C-H of L^2 is optionally $C-R^{20}$;

ring C is phenyl or pyridyl;

each R³ is independently selected from halogen, trihalomethyl, -CN,

 $-NO_2$, $-OR^4$, $-N(R^4)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^4)R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-N(R^4)SO_2R^4$, $-N(R^4)C(O)R^4$, $-NCO_2R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl

3

- C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide;
- two adjacent of R³, together with the annular atoms to which they are attached, can form a fiveto six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R²⁵;
- R^4 is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two of R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkenyl, and optionally substituted C₁₋₆alkynyl;
- R^7 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, -SO₂N(R^4) R^4 , -CO₂ R^4 , -C(=O)N(R^4) R^4 , -C(=N R^5)N(R^4) R^4 , -C(=N R^5) R^4 , -C(=O) R^4 , optionally substituted alkoxy, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl; and
- each of R^{10} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

4

provided:

312-913-0001

- 1) when both ring B and ring C are phenyl:
 - a) and the compound comprises ring B-CH₂N(H)C(=O)N(H)-ring C, then L¹ must be a single bond; R³ can not comprise a group of the formula

-O(CH₂)₂₋₄-N-piperazine that is *ortho*- to L^2 ; and ring A cannot be a 5-methyl-[1,2,4]-oxadiazol-3-yl radical, a 4H-[1,2,4]-oxadiazol-5-one-3-yl radical, nor a 4'-[2,2';6',2"]terpyridinyl radical;

- b) and L¹ is single bond, then L² cannot comprise -N(H)C(=O)C(=O)N(H)- nor -N(H)C(=Q)C(H)CNC(=O)- (where Q is S or O);
- c) and L¹ is other than single bond, then A cannot be quinolin-2-yl-L¹, quinolin-3-yl-L¹, or quinolin-4-yl-L¹;
- 2) when ring A is a fused aryl system, then L¹ must be a single bond;
- 3) when ring B is phenyl, ring C is a C_{6-16} carbocyclic, L^1 is a single bond, and the compound comprises –ring B-OCH₂C(=O)N(H)- then ring A cannot be a 2,5-dimethyl-1H-pyrrole-1-yl radical;
- 4) ring A cannot be a pyrimidin-2-yl radical when L¹ is -N(H)- and ring B is phenyl;
- 5) when the compound comprises the formula,

$$A$$
 B
 C

where V is =C(H)- or =N-, and there is a nitrogen of L^2 bound directly to ring B, then A can not comprise a [1,2,4]-oxadiazol-3-yl radical; and

6) the compound is not one of: N-1
yl)phenyl]oxy}acetamide, N-[4-(phenyl)phenyl]oxy}acetamide, N-(3,4-d)
yl)phenyl]oxy}acetamide, N-(2,3-d)
yl)phenyl]oxy}acetamide, N-(2,4-d)
yl)phenyl]oxy}acetamide, N-(2,5-d)
yl)phenyl]oxy}acetamide, N-(3,5-d)
yl)phenyl]oxy}acetamide, N-(3,5-d)
yl)phenyl]oxy}acetamide, N-(2,6-d)
yl)phenyl]oxy}acetamide, N-(2,6-d)

of: N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-N-[4-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1-N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-N-(2,6-dimethylphenyl)-2-{[3-(1H-tetrazol-1-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-dimethylphenyl)-2-{[3-(1H-tetrazol-1-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-dimethylphenyl)]oxy}-N-(2,4,6-dimethylphenyl)

trimethylphenyl)acetamide, $N-(2-ethylphenyl)-2-\{[3-(1H-tetrazol-1-$ N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, $N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1$ yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[2-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, $2-\{[3-(1H-tetrazol-1-yl)phenyl]oxy\}-N-[2$ yl)phenyl]oxy}acetamide, (trifluoromethyl)phenyl]acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-4-[({[3-(1H-tetrazol-1-(trifluoromethyl)phenyl]acetamide, methyl 4-[({[3-(1H-tetrazol-1ethyl yl)phenyl]oxy}acetyl)amino]benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl] yl)phenyl]oxy}acetyl)amino]benzoate, oxy\acetyl)amino\benzoic acid, N-[3-(methyloxy)phenyl]-2-\{[3-(1H-tetrazol-1-N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1Htetrazol-1-yl)phenyl]oxy}acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acet-amide, N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1and 1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide.

2-10. (Cancelled)

11. (original) The compound according to claim 10, wherein there exists at least one of R³ that is halogen.

- 12. (original) The compound according to claim 10, wherein there exists at least one of R³ that is trihalomethyl.
- 13. (original) The compound according to claim 10, wherein there exists at least one of R³ that is trifluoromethyl.
- 14. (original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical *meta* to L^2 .
- 15. (previously presented) The compound according to claim 10, wherein each of R^3 is independently selected from halogen, trihalomethyl, $-OR^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.
- 16. (currently amended) A compound for modulating c-Kit activity according to Formula II,

$$(R^{26})_{0-4}$$
 $(R^{30})_{1-5}$
 $(R^{30})_{1-5}$
 $(R^{30})_{1-5}$

II

or a pharmaceutically acceptable salt, thereof, wherein,

W is selected from the following:

$(\mathbb{R}^{27})_{0-4}$	$(R^{27})_{0-3}$	$(R^{27})_{0-3}$
Z	$Z = \frac{1}{11}$ $N = \frac{1}{N}$ $(R^{27})_{0-2}$	$(R^{27})_{0-1}$

N Z N (R ²⁷) ₀₋₁	$Z = \frac{1}{N}$ $N = \frac{1}{N}$ $(R^{27})_{0-1}$	Z N N 11 (R ²⁷) ₀₋₁
(R ²⁷) ₀₋₄ Y—Y Y=Y	$(R^{27})_{0-5} \xrightarrow{Y} Z$	$(R^{27})_{0-5} \xrightarrow{Y} \xrightarrow{Y} \xrightarrow{Z}$
$(R^{27})_{0-6} \xrightarrow{Y} \xrightarrow{Y} \xrightarrow{Y}$	$(R^{27})_{0-6} \underbrace{Y}_{Z} \underbrace{Y}_{Y}$	$(R^{27})_{0-6} \xrightarrow{Y} Y$

each of R^{27} independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁵⁵, -S(O)₀₋₂R⁵⁵, -SO₂N(R⁵⁵)R⁵⁵, -C(=O)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)R⁵⁵, -N(R⁵⁵)SO₂R⁵⁵, -N(R⁵⁵)C(O)R⁵⁵, -NCO₂R⁵⁵, -C(=O)R⁵⁵, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O)₀₋₂-, and -N(\mathbb{R}^7)-

E and G are each independently selected from -O-, -S(O)₀₋₂-, -C(R³¹)R³²-, and -N(R³³)-;

 J_1 and J_2 are each independently =C(H)- or =N-;

 R^{26} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heterocyclyl C_{1-6} alkyl;

 R^{30} is independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰,

- -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; or
- two adjacent of R²⁶ or two adjacent of R³⁰, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R³⁵;
- R^{31} and R^{32} are each independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R^{40}) R^{40} , -S(O)₀₋₂ R^{40} , -SO₂N(R^{40}) R^{40} , -CO₂ R^{40} , -C(=O)N(R^{40}) R^{40} , -C(=NR⁵⁰)N(R^{40}) R^{40} , -C(=NR⁵⁰)R⁴⁰, -N(R^{40})SO₂ R^{40} , -N(R^{40})C(O)R⁴⁰, -NCO₂ R^{40} , -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;
- R^{33} is selected from -H, optionally substituted lower alkyl, $-SO_2N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)N(R^{40})R^{40}$, $-C(=NR^{50})N(R^{40})R^{40}$, $-C(=NR^{50})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{40} is selected from -H, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^{50} is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted C₁₋₆alkenyl, and optionally substituted C₁₋₆alkynyl;

 R^{55} is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; and

two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.

- 17. (original) The compound according to claim 16, wherein the annular carbons of ring B to which W and E are attached are not contiguous.
- 18. (previously presented) The compound according to claim 17, wherein R^{30} is selected from halogen, trihalomethyl, $-OR^{40}$, $-N(R^{40})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl.
- 19. (original) The compound according to claim 18, wherein there exists at least one of R³⁰ that is trihalomethyl.
- 20. (original) The compound according to claim 18, wherein there exists at least one of R³⁰ that is trifluoromethyl.
- 21. (previously presented) The compound according to claim 18, according to formula III.

$$W = \begin{pmatrix} (R^{26})_{0-4} \\ E \end{pmatrix} \begin{pmatrix} H \\ 0 \end{pmatrix} \begin{pmatrix} (R^{30})_{1-5} \\ (R^{30})_{1-5} \end{pmatrix}$$
III

22. (currently amended) The compound according to claim 21, wherein W is selected from the

following:

$(\mathbb{R}^{27})_{0-4}$	$(R^{27})_{0-3}$	$(R^{27})_{0-3}$
$(R^{27})_{0-1}$	$Z = \frac{1}{11}$ $N = \frac{1}{N}$ $(R^{27})_{0-2}$	$(R^{27})_{0-1}$
(R ²⁷) ₀₋₁	$\frac{Z}{\frac{1}{N}}$ $(R^{27})_{0-1}$	Z N N N N N N N N N N N N N N N N N N N
(R ²⁷) ₀₋₄	(R ²⁷) ₀₋₅ Y Z	$(R^{27})_{0-5}$
(R ²⁷) ₀₋₆ Y Y	(R ²⁷) ₀₋₆ Y Y	$(R^{27})_{0-6} \xrightarrow{Y} Y$

and R²⁷ is defined as above.

- 23. (withdrawn) The compound according to claim 22, wherein E is selected from -O-, $-S(O)_{0-2}$ -, and -NH-; and G is -CH₂-.
- 24. (withdrawn) The compound according to claim 22, wherein E is either -CH₂- or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (Cancelled)
- 26. (original) The compound according to claim 25, wherein at least one of R^{30} is a trifluoromethyl radical *meta* to -E-G-C(=O)N(H)-.
- 27. (currently amended) The compound according to claim 1, selected from Table 3:

Table 3

Entry	Name	Structure
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C, 0 H _N N, N
2	N-phenyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
3	N-(2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N H ₃ C
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N CI
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N=N CI

Table 3

Entry	Name	Structure
6	ethyl 2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate	N.N.N.
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N CH ₃ CI
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N N N N N
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	F F CI
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N CH ₃
12	N-(4-morpholin-4-ylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N F F F F F F F F F F F F F F F F F

Table 3

Entry	Name	Structure
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CH ₃ H F F F CI
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH ₃ O N F F
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ H F F F CI
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N O O CH ₃
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N-N-N-N-F-F

Table 3

Entry	Name	Structure
21	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2,5-dioxopyrrolidin-1- yl)phenyl]oxy}acetamide	ON CI FFF
22	(2E)-N-[4-chloro-3- (trifluoromethyl)phenyl]-3-[3-(1H- tetrazol-1-yl)phenyl]prop-2-enamide	N=N CI
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N.N.
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H ₃ C CI
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	NNN S N FFF
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N P F F
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CI F N N N=N
29	methyl 1-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-1,2,3-triazole-4- carboxylate	H ₃ C, O CI F F F
30	1,1-dimethylethyl {4-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	

Table 3

Entry	Name	Structure
31	1,1-dimethylethyl {4-[({[4-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carba mate	N. N
32	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N = N CH3
33	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N CH ₃
34	N-(4-aminophenyl)-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N.N.
35	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N-ONH H ₃ C H ₃ C

Table 3

Entry	Name	Structure
36	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N=N. N- N- N- N- N- N- N- N- N- N- N- N- N-
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N CI F F
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CH ₃ O CH ₃ F F
39	N-1,3-benzothiazol-2-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
40	N-quinolin-8-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH ONN NN

Table 3

Entry	Name	Structure
41	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	O NH N-N'N
42	N-isoquinolin-5-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH ONN N-N'N
43	N-{3-[(phenylmethyl)oxy]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH N-N, N
44	N-[5-methyl-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C OCH ₃ NH N-N N
45	N-[2,5-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	H ₃ C-O NH N-N'N

Table 3

Entry	Name	Structure
46	N-(6-fluoro-1,3-benzothiazol-2-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	F S H
47	methyl 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzoate	H ₃ C.O CO NH N-N, N
48	5-chloro-2-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzamide	N.N. H. CI
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N, N, N H CI CH ₃
50	N-[2-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	NH ON N.

Table 3

Entry	Name	Structure
51	N-[3-(aminosulfonyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N.N. N. H.
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N, N, N N, N N, N N, N N, N N, N N, N N
53	N-(4-{[(4- methylphenyl)sulfonyl]amino}phenyl)-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ O:S:O N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N
54	N-(5-phenyl-1H-pyrazol-3-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N-N N-N N-N
55	N-1,3-benzothiazol-2-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N

Table 3

Entry	Name	Structure
56	N-quinolin-8-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1H-pyrrole-1-carboxylate	CI F F F
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	CI F N H
59,	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	N O N F F
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	N.N.N.O.N.F.F.F
61	4-chloro-N-(2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}ethyl)-3- (trifluoromethyl)aniline	N, N O N F F

Table 3

Entry	Name	Structure
62	N-[4-chloro-3-(trifluoromethyl)phenyl]-N- (2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}ethyl)formamide	N-N-N-O-N-FFF
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	N CI FF F F F F F F F F F F F F F F F F F
64	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-3-ylphenyl)oxy]acetamide	CI FF F
65	(2E)-N-[4-fluoro-3- (trifluoromethyl)phenyl]-3-[3-(1H- tetrazol-1-yl)phenyl]prop-2-enamide	N N N F F F F F F F F F F F F F F F F F
66	N-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]propanamide	N N S F F F F F F F F F F F F F F F F F

Table 3

Entry	Name	Structure
67	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[6-(1H-tetrazol-1-yl)pyrimidin-4- yl]oxy}acetamide	N N H F F CI
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	H_3C CH_3 $N-O$ CH_3
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	CI F NH F
70	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-furan-2-ylphenyl)oxy]acetamide	O N F F
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N, N, N, H, H, F, F

Table 3

Entry	Name	Structure
72	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-dibenzo[b,d]furan-4- ylphenyl)oxy]acetamide	F F CI
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N O H F F CI
74	N-methyl-N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N O O CH ₃
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	HN CI FF F
76	N-[4-chloro-3-(trifluoromethyl)phenyl]-N- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ N=N CI FF

Table 3

Entry	Name	Structure
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	THE PERSON SERVICES OF
78	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(pyridin-2- ylamino)phenyl]oxy}acetamide	H O N F F F F F
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	F F N N H F
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	C F F F
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N N F F

Table 3

Entry	Name	Structure
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	CI NH NH F F
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	CI NH NH FF
. 84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	TZ ZZ Z
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	P F F F F F F F F F F F F F F F F F F F
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	N, N, N, H, F, F

Table 3

Entry	Name	Structure
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	N N N N N N N N N N N N N N N N N N N
, 88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H_3C $N = N$ $N = N$
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	O N F F F F
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F O N F F F F F F F F F F F F F F F F F
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	FON N F F F F F F F F F F F F F F F F F

Table 3

Entry	Name	Structure
92	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzenesulfonamide	N N N N N N N N N N N N N N N N N N N
93	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- N-methyl-3-(1H-tetrazol-1- yl)benzenesulfonamide	N O O O C F F F CH ₃
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	ON FFF NH FF
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C, O N F F F
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide	H_3C O N F F F F

Table 3

Entry	Name	Structure
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	O N F F
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H ₃ CON H F F F F N N=N
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N N F F
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N N N N N N N N N N N N N N N N N
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (2,3,5,6-tetrafluoro-4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	F F F F F

Table 3

Entry	Name	Structure
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	N N N F F
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	H. N. H. F. F.
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N N N N F F
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}propanamide	N N N N N N N N N N N N N N N N N N N
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	O CH ₃ F F

Table 3

Entry	Name	Structure
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	$\begin{array}{c c} & & & & \\ & &$
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C.ONNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C·O N N N F F
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C ₀ N N H H F F
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C ₀ N F F

Table 3

Entry	Name	Structure
112	1,1-dimethylethyl 2-{4-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-indole-1- carboxylate	CI F F F
113	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 4-(1H-tetrazol-1-yl)benzenesulfonamide	O O O F S N N F N=N
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	HN.N HN.N HN.N
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	FO O H FF N=N
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F F

Table 3

Entry	Name	Structure
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N O N F F F
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	H, N, N, H H F F F
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	H.N.N.H.F.F
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON FFF

Table 3

Entry	Name	Structure
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	CI F F F
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	H N N N F F
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	N N N F F

Table 3

Entry	Name	Structure
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyrimidin-5-ylphenyl)methyl]urea	CI O CH ₃
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyridin-3-ylphenyl)methyl]urea	N N N O CH ₃
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	CI O-CH ₃ O-CH ₃
130	(4-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	ON CH ₃ CCH ₃ CCH ₃
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CH ₃ O CI F F

Table 3

Entry	Name	Structure
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CH ₃ O N F F
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyridin-3-ylphenyl)methyl]urea	N O CH ₃
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyrimidin-5-ylphenyl)methyl]urea	N N N N O CH ₃
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N O CH ₃
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N O CH ₃ CI O CH ₃ CH ₃

Table 3

Entry	Name	Structure
137	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-(3-pyrimidin-5-ylphenyl)hydrazinecarboxamide	CH ₃ O CI N N N N F F
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	P F F F
139	N-{[3-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N CI F F F
140	N-{[4-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N
141	N-{[3-(2-aminopyrimidin-5-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N O CI F F F

Table 3

Entry	Name	Structure
142	N-{[4-(2-aminopyrimidin-5-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₂ N N
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH ₃ O CI N N F F
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	CH ₃ O CI P N N P F
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	CI F NH
146	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (isoquinolin-7-yloxy)acetamide	F F CI

Table 3

Entry	Name	Structure
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	CC F F F F S S S S S S S S S S S S S S S
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	N CI F N N H F
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N O CI F N H H F
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	N CI F F F
151	methyl 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2-carboxylate	CH ₃ O O N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	N N N N F F
153	N-{[3-(2-amino-5-methylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CH ₃ OH ₂ NH ₂ OH ₃ NH ₂ F
154	methyl 3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazine-2- carboxylate	H ₃ C ₀ N N F F
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	$N = N$ $N = N$ $O = N$ $O = CH_3$ $O = CH_3$
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3- (1H-tetrazol-1-yl)phenyl]methyl}urea	$N = N$ $N = N$ $O = CI$ $O = CH_3$

Table 3

Entry	Name	Structure
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N F F
158	N-{[3-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N NH2 O CI F F F F F
159	N-{[4-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH ₂
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N N N N N N F F
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N CI F F

Table 3

Entry	Name	Structure
162	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(pyrimidin-2- yloxy)phenyl]methyl}urea	N N N N F F
163	N-({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)- 3-(1H-tetrazol-1-yl)benzamide	N N N N N F F
164	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[2- (dimethylamino)ethyl]pyrazine-2- carboxamide	HN O HN O HN O
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N N N N F F
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C.O.

Table 3

Entry	Name	Structure
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	N N N F F
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	N O CH ₃
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N
170	N-{[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	F N N N CF ₃
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C CI N H H F F

Table 3

Entry	Name	Structure
172	N-{[4-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N NH ₂ CI CF ₃
173	N-{[3-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CC F F F
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C CI N F F
175	[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F F F F
176	[3-(2-aminopyridin-3-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	NH ₂ ON FF

Table 3

Entry	Name	Structure
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI N F F
178	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(hydroxymethyl)pyridin-3- yl]phenyl}methyl)urea	HO N CF ₃
179	N-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C N CF ₃
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	CN N O CF ₃
181	1,1-dimethylethyl (3S)-3-({[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	FFFCI HN NN N

Table 3

Entry	Name	Structure .
182	3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	HN FF CI HN O HN O N HN O
183	1,1-dimethylethyl (3S)-3-({[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	FF F CI NH HN O H ₂ N N
184	3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	FF F CI NH NH NH NH NH NH NH NN N
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N O N F F

Table 3

Entry	Name	Structure
186	N-{[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	F NH ₂ O CI NH ₂ F F
187	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N N N N O N F F
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI F F F
189	[3-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₂ N O N F F
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	S N N N CF ₃

Table 3

Entry	Name	Structure
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C N
192	[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	F N NH ₂
193	[4-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F F F F
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CI N N N
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name ,	Structure
196	[4-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₂ N CH ₃
197	[3-(1H-tetrazol-1-yl)phenyl]methyl 1,3- benzothiazol-2-ylcarbamate	
198	[3-(1H-tetrazol-1-yl)phenyl]methyl (5- bromopyridin-2-yl)carbamate	N N N N Br
199	(3-pyridin-3-ylphenyl)methyl (3,5- dimethylphenyl)carbamate	CH ₃ CH ₃ CH ₃
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH ₃ ON N CI

Table 3

Entry	Name	Structure
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O N F F
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro- 2-(methyloxy)phenyl]carbamate	CH ₃ ON N N CI
203	(4-pyrimidin-5-ylphenyl)methyl (3,4-dimethylphenyl)carbamate	ON CH ₃
204	(3-pyridin-3-ylphenyl)methyl (3,4- dimethylphenyl)carbamate	ON CH ₃
205	1,1-dimethylethyl 3-({[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	FFFCI HN O HN O H ₂ N N N O

Table 3

Entry	Name	Structure
206	1,1-dimethylethyl 3-({[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}amino)piperidine-1- carboxylate	F F CI HN NH NH NH NN NH NN NN NN N
207	3-amino-6-(3-{[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)-N-piperidin-3- ylpyrazine-2-carboxamide	HN HN O HN O
208	3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-N-piperidin-3-ylpyrazine-2-carboxamide	F F F CI NH NN
209	1,1-dimethylethyl 4-{[3-amino-6-(3- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	CI FF F O NH

Table 3

Entry	Name	Structure
210	1, I-dimethylethyl 4-{[3-amino-6-(4- {[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)a mino]methyl}phenyl)pyrazin-2- yl]carbonyl}piperazine-1-carboxylate	F F CI NH O HN N N N N N N N N N N N N N N N N
211	N-({3-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	H ₂ N HN O
212	N-({4-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)- N'-[4-chloro-3- (trifluoromethyl)phenyl]urea	FFF CI NH NN NN NN NN NN NN NN NN NN NN NN NN
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N N CF ₃

Table 3

Entry	Name	Structure
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF ₃
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N CF ₃
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CF ₃ CI
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N CI O CI CF ₃
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI NH CF ₃

Table 3

Entry	Name	Structure
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N F CI N N CF ₃
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	F N N CF ₃
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	N N N N N N N N N N N N N N N N N N N
222	[3-(1H-tetrazol-1-yl)phenyl]methyl [6- (trifluoromethyl)pyridin-2-yl]carbamate	N N N F F
223	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- (trifluoromethyl)pyridin-2-yl]carbamate	N N N F F

Table 3

Entry	Name	Structure
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H ₃ C ^{-S} CI N CF ₃
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C ON CF ₃
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	O-CH ₃ O-CH ₃ O-CH ₃ CCI CF ₃
227	2,3'-bipyridin-6-ylmethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F
228	(6-pyrimidin-5-ylpyridin-2-yl)methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	$\begin{pmatrix} N \\ F \\ F \\ F \\$

Table 3

Entry	Name	Structure
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	H CF ²
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	N N CF ₃
231	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate	N N F F F
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CI N N N F F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	ON FF F

28. (previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

29. (cancelled)

(withdrawn) A method for modulating the in-vivo activity of a kinase, the method 30. comprising administering to a subject an effective amount of the compound according to -claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{[3- $N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-$ (1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}acetamide, acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl] oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-[2-N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, acetamide, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, $N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1$ yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(4-chloro-3acetamide, methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, Ntetrazol-1-yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1-4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] ethyl benzoate, yl)phenyl]oxy}acetyl)amino] benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-[2-chloro-5acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, (trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-

312-913-0001

N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy} acetamide, and yl)phenyl]oxy} acetamide.

- (withdrawn) The method according to claim 30, wherein the kinase is c-Kit. 31.
- (withdrawn) The method according to claim 31, wherein modulating the in vivo activity 32. of c-Kit comprises inhibition of c-Kit.
- 33. (withdrawn) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in claim 1 or a compound, or a pharmaceutical composition comprising said compound, selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl) acetamide, N-(2-ethyl-phenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy} acetamide, N-[2,4-bis(methyl-oxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)-phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy} acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1-

yl)phenyl]oxy}acetyl)amino] 4-[({[3-(1H-tetrazol-1ethyl benzoate, yl)phenyl]oxy}acetyl)amino] benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy} acetyl) amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-N-[4-chloro-3acetamide, (trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} (trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy} acetamide, and yl)phenyl]oxy} acetamide.

(withdrawn) A method of screening for modulators of c-Kit, the method comprising 34. combining the compound according to claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} acetamide, acetamide, N-(2,3-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{[3-N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-(2,4,6yl)phenyl]oxy}acetamide, trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1phenyl]-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} N-[2-(ethyloxy) acetamide, N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}acetamide, acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-

312-913-0001

4-[({[3-(1H-tetrazol-1acetamide, methyl N-[3-(trifluoromethyl) phenyl] 4-[({[3-(1H-tetrazol-1benzoate, ethyl yl)phenyl]oxy}acetyl)amino] yl)phenyl]oxy}acetyl)amino] benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, (trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} N-(4acetamide, chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1acetamide, and tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy} acetamide, and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.

(withdrawn) A method of inhibiting proliferative activity in a cell, the method 35. comprising administering an effective amount of a composition comprising the compound according to claim 1 or a compound selected from N-naphthalen-1-yl-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{[3-N-(2,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-° acetamide, (1H-tetrazol-1-yl)phenyl]oxy} N-(3,5-dimethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} yl)phenyl]oxy}acetamide, acetamide, N-(2,6-dimethyl-phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]ox tetrazol-1-yl)phenyl] oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{[3-(1Htetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-[2-N-(2,6-diethylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, acetamide, (methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2- $N-[3-(ethyloxy)phenyl]-2-{[3-(1H-tetrazol-1-$ {[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, Ntetrazol-1-yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}

acetamide, N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} 2-{[3-(1H-tetrazol-1tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoro-methyl)phenyl] acetamide, yl)phenyl]oxy}-N-[3-(trifluoromethyl) phenyl] acetamide, methyl 4-[({[3-(1H-tetrazol-1-4-[({[3-(1H-tetrazol-1yl)phenyl]oxy}acetyl)amino] benzoate, ethyl yl)phenyl]oxy}acetyl)amino] benzoate, 3-[({[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl)amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4acetamide, N-[2-chloro-5-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, (trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, N-(4-aminophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl] oxy} acetamide, tetrazol-1-yl)phenyl]oxy} and N-(4-acetylphenyl)-2-{[3-(1H-tetrazol-1yl)phenyl]oxy} acetamide, to a cell or a plurality of cells.